Goldstone Anthony P
Imaging Sciences Department, MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital Campus, London W12 0NN, UK.
Prog Brain Res. 2006;153:57-73. doi: 10.1016/S0079-6123(06)53003-1.
Obesity is a major global epidemic, with over 300 million obese people worldwide, and nearly 1 billion overweight adults. Being overweight carries significant health risks, reduced quality of life, and impaired socioeconomic success, with profound consequences for health expenditure. The most successful treatment for obesity is gastric bypass surgery, which acts in part by reducing appetite through alterations in gut hormones. Circulating gut hormones, secreted or suppressed after eating food, act in the brain, particularly the hypothalamus, to alter hunger and fullness. Stomach-derived ghrelin increases food intake even in those with anorexia from chronic illness, while pancreatic polypeptide (PP), intestinal peptide YY 3-36 (PYY), oxyntomodulin, and other hormones reduce food intake and appetite. While obese subjects have appropriate reductions in orexigenic ghrelin, other gut-hormone disturbances may contribute to obesity such as reduced anorexigenic PYY and PP. Prader-Willi syndrome (PWS) arises from the loss of paternally inherited genes on chromosome 15q11-13, leading to life-threatening insatiable hunger and obesity from early childhood, through developmental brain, particularly hypothalamic defects. The study of genetically homogenous causes of abnormal-feeding behavior helps our understanding of appetite regulation. PWS subjects have inappropriately elevated plasma ghrelin for their obesity, at least partly explained by preserved insulin sensitivity. It remains unproven if their hyperghrelinemia or other gut-hormone abnormalities contribute to the hyperphagia in PWS, in addition to brain defects. Postmortem human hypothalamic studies and generation of animal models of PWS can also provide insight into the pathophysiology of abnormal-feeding behavior. Changes in orexigenic NPY and AGRP hypothalamic neurons, or anorexigenic oxytocin neurons have been found in illness and PWS. Functional neuroimaging studies, using PET and fMRI, will also allow us to tease apart the hormonal and brain pathways responsible for controlling human appetite, and their defects in obesity.
肥胖是一种主要的全球流行病,全球有超过3亿肥胖者,近10亿超重成年人。超重会带来重大的健康风险、降低生活质量并损害社会经济成就,对医疗支出产生深远影响。肥胖最成功的治疗方法是胃旁路手术,其部分作用是通过改变肠道激素来降低食欲。进食后分泌或抑制的循环肠道激素作用于大脑,特别是下丘脑,以改变饥饿感和饱腹感。胃源性ghrelin即使在患有慢性病导致厌食的人群中也会增加食物摄入量,而胰多肽(PP)、肠肽YY 3-36(PYY)、胃泌酸调节素和其他激素会减少食物摄入量和食欲。虽然肥胖受试者的促食欲ghrelin会适当减少,但其他肠道激素紊乱可能导致肥胖,如厌食性PYY和PP减少。普拉德-威利综合征(PWS)源于15号染色体q11-13上父系遗传基因的缺失,导致从幼儿期就出现危及生命的无法满足的饥饿和肥胖,这是由发育性脑缺陷,特别是下丘脑缺陷引起的。对异常进食行为的基因同质原因的研究有助于我们理解食欲调节。PWS患者因肥胖而血浆ghrelin不适当升高,这至少部分可以通过保留的胰岛素敏感性来解释。除了脑缺陷外,他们的高ghrelin血症或其他肠道激素异常是否导致PWS中的食欲亢进仍未得到证实。对人类下丘脑的尸检研究和PWS动物模型的建立也可以深入了解异常进食行为的病理生理学。在疾病和PWS中发现了促食欲的下丘脑神经肽Y(NPY)和刺鼠肽相关蛋白(AGRP)神经元或厌食性催产素神经元的变化。使用正电子发射断层扫描(PET)和功能磁共振成像(fMRI)的功能神经影像学研究也将使我们能够区分负责控制人类食欲的激素和脑通路及其在肥胖中的缺陷。